Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
Conclusions/interpretationCanagliflozin decreased KIM-1 and modestly reduced TNFR-1 and TNFR-2 compared with placebo in individuals with type 2 diabetes in CANVAS. Early decreases in TNFR-1 and TNFR-2 during canagliflozin treatment were independently associated with a lower risk of kidney disease progression, suggesting that TNFR-1 and TNFR-2 have the potential to be pharmacodynamic markers of response to canagliflozin.Graphical abstract
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Invokana | SGLT2 Inhibitors | Sodium | Study | Urology & Nephrology